Data About Zetia Risks Was Not Fully Revealed
36441
New evidence shows that drug makers Merck and Schering-Plough never published several studies that raised questions about a cholesterol drugâs risks to the liver.
520589
Investors are discouraged after it releases the latest data for its top drug.
91603
Weighing the risks of Avandia, a diabetes drug, against its benefits is a difficult task.
365737
The safety of Merck&#39;s (MRK:NYSE - news - research) Vioxx has been questioned again with the posting of an internal Food and Drug Administration study on the agency&#39;s website.
346497
An FDA review of AstraZeneca Plc&#39;s (AZN.L: Quote, Profile, Research) (AZN.N: Quote, Profile, Research) Exanta questioned the experimental drug&#39;s
32044
High doses of Zocor provide no benefits in preventing new problems in heart attack patients: study. MUNICH  - Merck&#39;s anti-cholesterol drug Zocor suffered a setback after a major study found high
345190
Federal advisers heard conflicting data today about the safety of new drug-oozing stents used to keep clogged arteries open as the experts struggled to advise government regulators about whether the risks of the devices outweigh their benefits for millions of patients.
319964
The embattled pharmaceutical industry announced its intention Thursday to publish more data about clinical drug trials, despite skepticism about whether the initiative will really increase transparency and improve drug safety.
33756
Schering-Plough Corp and Merck & Co are defending their shared cholesterol treatments, Vytorin and Zetia, in advertisements after a failed study generated negative publicity.
115250
A high-dose regimen of Merck&#39;s cholesterol drug Zocor offered no conclusive benefits over a low-cholesterol diet and a lower dose of Zocor in preventing a recurrence of cardiac events
488480
RECENT press reports, which resurrected old safety concerns about nevirapine are deceptive, insincere and meant to mislead. They could not have been in the best interest of children or HIV-positive mothers.
390715
AstraZeneca Plc. said on Wednesday a new  study in Japan showed a higher rate of a potentially fatal side  effect in patients taking its lung cancer pill Iressa than that  demonstrated in an earlier analysis.
693379
questions over testing of a key HIV/AIDS drug before a US-backed roll-out of the treatment across the continent. Ingelheim to hide adverse effects of nevirapine when used to try to prevent mother-to-child HIV transmission.
512456
NEW YORK, September 9 (New Ratings) - The FDA has raised questions regarding AstraZenecaâs (AZN.NYS) blood thinner, Exanta. The leading pharmaceutical companyâs hopes had been pinned on Exanta, which
99984
Sept. 14, 2004 -- In a study of people with heart disease, results show that high doses of the popular cholesterol-lowering drug Zocor may not prevent heart disease deaths and heart attacks -- and may cause muscle damage.
152719
An advisory panel said that the first drug to enhance the sex drive of women should not be approved because of a lack of information about its long-term safety.
421195
Drug-coated stents may carry a delayed risk of potentially dangerous blood clots, according to a new report.